Seattle Genetics is a biotechnology company that creates monoclonal antibody-based therapeutics to treat serious medical conditions. The company develops a broad variety of clinical and pre-clinical product candidates aimed at treating different types of cancer. It is also a leader in antibody technologies especially antibody-drug conjugate (ADC) platform.
For nearly 20 years, designed monoclonal antibodies have benefited cancer patients, people with autoimmune diseases and other acute medical conditions. Antibody-based therapies have advanced the treatment of cancer by targeting malignant cells and eliminating the damage to ordinary tissues. The outcome of this is better-tolerated therapies that can be used with chemotherapy to enhance patient outcomes without large increases in toxicities.
The firm is headquartered in Bothell, Washington and was founded in 1997. The company joins forces with other research companies and has made remarkable advancements in developing an effective treatment. It has agreements with several organizations such as Medarex, Bristol-Myers Squibb, and Genencor International. Seattle Genetics holds license agreements for its ADC technology with Eos Biotechnology, Celltech Group, and Genencor.
Since establishment, Seattle Genetics has grown and currently provides drugs to 50 countries around the world. As a result of the company’s increased collaborative efforts and effectiveness of their products, it has expanded to employ more than 600 staff. The company has achieved great milestones in the previous years such as initiating clinical trials of SGN-30, improving several clinical trials of SGN-15 and collaboration with other biotechnology companies. Dr. Clay Siegall has been integral to the company’s achievements.
Dr. Clay Siegall is the co-founder and CEO of Seattle Genetics. He is also the chairperson of the company’s board. In January 2013 he was appointed a member of the Board of Directors at Mirna Therapeutics. Dr. Siegall studied Zoology at the University of Maryland and holds a PhD in Genetics from the George Washington University. In 2013, the University of Maryland named Dr. Siegall the alumnus of the year for Math, Computer, and Natural Sciences.
Dr. Siegall is passionate about improving the lives of cancer patients and those with chronic illnesses. The scientist has built Seattle Genetics on a foundation of rigorous research, innovation, and drug development practices. Through Clay Siegall’s leadership, Seattle Genetics has seen substantial growth. Dr. Siegall has also helped the company raise more than $675 million to fund its research and training initiatives.
Read their reviews here: